EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische Studie

Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer

Ying Cheng, David R Spigel, Byoung Chul Cho iD, Konstantin K Laktionov, Jian Fang, Yuanbin Chen, Yoshitaka Zenke, Ki Hyeong Lee, Qiming Wang, Alejandro Navarro, Reyes Bernabe, Eva Lotte Buchmeier und 13 weitere

New England Journal of Medicine · 10.10.2024 · 391 (14) · 1313-1327

DOI: 10.1056/nejmoa2404873 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 10.10.2024. Verfasst von Ying Cheng und 24 weiteren Autor:innen. Beteiligte Einrichtung: From Jilin Cancer Hospital, Changchun (Y. Cheng), Department II of Thoracic Oncology (J.F.) and the Department of Radiation Oncology (A.S.), Key Labo…. Hauptthemen laut MEDLINE: Lung Neoplasms, Small Cell Lung Carcinoma, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 373-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsSmall Cell Lung CarcinomaAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedChemoradiotherapyAntineoplastic Combined Chemotherapy ProtocolsProgression-Free SurvivalHumansFemaleMaleMiddle AgedDouble-Blind MethodAgedAdultNeoplasm StagingKaplan-Meier EstimateChemotherapy, AdjuvantCranial IrradiationSurvival AnalysisAntineoplastic Agents, Immunological

Substanzen

durvalumabtremelimumabAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • From Jilin Cancer Hospital, Changchun (Y. Cheng), Department II of Thoracic Oncology (J.F.) and the Department of Radiation Oncology (A.S.), Key Laboratory of Carcinogenesis and Translational Research (Ministry of Educa…

ORCID-Profile: Byoung Chul Cho

Förderung

  • AstraZeneca

Zitieren

APA

Cheng, Y., Spigel, D. R., Cho, B. C., Laktionov, K. K., Fang, J., Chen, Y., Zenke, Y., Lee, K. H., Wang, Q., Navarro, A., Bernabe, R., Buchmeier, E. L., Chang, J. W., Shiraishi, Y., Sezgin Goksu, S., Badzio, A., Shi, A., Daniel, D. B., Hoa, N. T. T., …, & ADRIATIC Investigators (2024). Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer. New England Journal of Medicine, 391(14), 1313-1327. https://doi.org/10.1056/nejmoa2404873

Vancouver

Cheng Y, Spigel DR, Cho BC, Laktionov KK, Fang J, Chen Y, et al. Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer. New England Journal of Medicine. 2024;391(14):1313-1327. doi:10.1056/nejmoa2404873

BibTeX
@article{Cheng2024,
  author = {Cheng, Ying and Spigel, David R and Cho, Byoung Chul and Laktionov, Konstantin K and Fang, Jian and Chen, Yuanbin and Zenke, Yoshitaka and Lee, Ki Hyeong and Wang, Qiming and Navarro, Alejandro and Bernabe, Reyes and Buchmeier, Eva Lotte and Chang, John Wen-Cheng and Shiraishi, Yoshimasa and Sezgin Goksu, Sema and Badzio, Andrzej and Shi, Anhui and Daniel, Davey B and Hoa, Nguyen Thi Thai and Zemanova, Milada and Mann, Helen and Gowda, Hema and Jiang, Haiyi and Senan, Suresh and ADRIATIC Investigators, ADRIATIC Investigators},
  title = {Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer},
  journal = {New England Journal of Medicine},
  year = {2024},
  volume = {391},
  number = {14},
  pages = {1313--1327},
  doi = {10.1056/nejmoa2404873}
}
Kostenlos starten →